LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX · IEX Real-Time Price · USD
2.060
-0.040 (-1.90%)
At close: Jul 19, 2024, 4:00 PM
1.970
-0.090 (-4.37%)
Pre-market: Jul 20, 2024, 9:29 AM EDT

LAVA Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Ending
CurrentDec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Market Capitalization
544292142--
Market Cap Growth
100.60%-54.86%-35.10%---
Enterprise Value
-42-58-44-4-14-6
PE Ratio
--0.89-2.71-2.94--
PS Ratio
3.975.524.4623.32--
PB Ratio
0.980.731.001.05--
P/FCF Ratio
-2.52-0.9425.03-4.24--
P/OCF Ratio
-2.54-0.9621.39-4.35--
EV/Sales Ratio
-0.63-7.66-2.11-0.67-3.13-
EV/EBITDA Ratio
0.271.201.310.090.780.60
EV/EBIT Ratio
0.261.161.280.090.760.58
EV/FCF Ratio
0.251.31-11.840.121.200.59
Debt / Equity Ratio
0.120.120.060.040.540.30
Debt / EBITDA Ratio
-0.21-0.15-0.18-0.12-0.27-0.19
Debt / FCF Ratio
-0.19-0.161.58-0.17-0.42-0.19
Quick Ratio
7.326.496.2011.872.315.20
Current Ratio
7.426.626.4012.142.485.35
Asset Turnover
0.120.060.140.040.26-
Interest Coverage
----66.52-45.44-111.64
Return on Equity (ROE)
-51.90%-68.50%-33.50%-37.00%-236.60%-
Return on Assets (ROA)
-26.30%-35.70%-23.70%-31.30%-108.80%-
Return on Capital (ROIC)
-55.75%-75.23%-38.08%-35.39%-125.38%-125.94%
Earnings Yield
-57.37%-112.28%-36.89%-33.95%--
FCF Yield
-64.16%-106.20%4.00%-23.58%--
Buyback Yield / Dilution
-1.92%-3.12%-31.21%-4850.36%10.81%-
Total Shareholder Return
-1.92%-3.12%-31.21%-4850.36%10.81%-
Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).